• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拓展配体苯环核心结构多样性以靶向 von Hippel-Lindau E3 泛素连接酶:高效低氧诱导因子-1α稳定剂的研发。

Expanding the Structural Diversity at the Phenylene Core of Ligands for the von Hippel-Lindau E3 Ubiquitin Ligase: Development of Highly Potent Hypoxia-Inducible Factor-1α Stabilizers.

机构信息

Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.

Centre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, 1 James Lindsay Place, Dundee, Scotland DD1 5JJ, U.K.

出版信息

J Med Chem. 2023 Sep 28;66(18):12776-12811. doi: 10.1021/acs.jmedchem.3c00434. Epub 2023 Sep 14.

DOI:10.1021/acs.jmedchem.3c00434
PMID:37708384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10544018/
Abstract

Hypoxia-inducible factor-1α (HIF-1α) constitutes the principal mediator of cellular adaptation to hypoxia in humans. The HIF-1α protein level and activity are tightly regulated by the ubiquitin E3 ligase von Hippel-Lindau (VHL). Here, we performed a structure-guided and bioactivity-driven design of new VHL inhibitors. Our iterative and combinatorial strategy focused on chemical variability at the phenylene unit and encompassed further points of diversity. The exploitation of tailored phenylene fragments and the stereoselective installation of the benzylic methyl group provided potent VHL ligands. Three high-resolution structures of VHL-ligand complexes were determined, and bioactive conformations of these ligands were explored. The most potent inhibitor () exhibited dissociation constants lower than 40 nM, independently determined by fluorescence polarization and surface plasmon resonance and an enhanced cellular potency, as evidenced by its superior ability to induce HIF-1α transcriptional activity. Our work is anticipated to inspire future efforts toward HIF-1α stabilizers and new ligands for proteolysis-targeting chimera (PROTAC) degraders.

摘要

缺氧诱导因子-1α(HIF-1α)是人类细胞对缺氧适应的主要介质。HIF-1α 蛋白水平和活性受到泛素 E3 连接酶 von Hippel-Lindau(VHL)的严格调节。在这里,我们进行了基于结构和基于生物活性的新型 VHL 抑制剂设计。我们的迭代和组合策略专注于苯环单元的化学可变性,并包含了更多的多样性点。定制苯环片段的利用和苄基甲基的立体选择性安装提供了有效的 VHL 配体。确定了三个 VHL-配体复合物的高分辨率结构,并探索了这些配体的生物活性构象。最有效的抑制剂()表现出低于 40 nM 的解离常数,这是通过荧光偏振和表面等离子体共振独立确定的,并且具有增强的细胞效力,这表现为其诱导 HIF-1α 转录活性的能力更优。我们的工作预计将激发未来对 HIF-1α 稳定剂和新的 PROTAC 降解剂配体的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/e1f16c4c333c/jm3c00434_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/63e8a826da4b/jm3c00434_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/241b441fbe45/jm3c00434_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/edee05507c87/jm3c00434_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/dec6877f5048/jm3c00434_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/8b70f76d4162/jm3c00434_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/bdb23521b954/jm3c00434_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/0630668f2ddb/jm3c00434_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/81d3db17b5b8/jm3c00434_0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/7dc7a0de4088/jm3c00434_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/45cf7824b4f7/jm3c00434_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/a4e3ce0217b4/jm3c00434_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/b4772d4a6173/jm3c00434_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/f2fb708390ca/jm3c00434_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/e1f16c4c333c/jm3c00434_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/63e8a826da4b/jm3c00434_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/241b441fbe45/jm3c00434_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/edee05507c87/jm3c00434_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/dec6877f5048/jm3c00434_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/8b70f76d4162/jm3c00434_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/bdb23521b954/jm3c00434_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/0630668f2ddb/jm3c00434_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/81d3db17b5b8/jm3c00434_0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/7dc7a0de4088/jm3c00434_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/45cf7824b4f7/jm3c00434_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/a4e3ce0217b4/jm3c00434_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/b4772d4a6173/jm3c00434_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/f2fb708390ca/jm3c00434_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e318/10544018/e1f16c4c333c/jm3c00434_0010.jpg

相似文献

1
Expanding the Structural Diversity at the Phenylene Core of Ligands for the von Hippel-Lindau E3 Ubiquitin Ligase: Development of Highly Potent Hypoxia-Inducible Factor-1α Stabilizers.拓展配体苯环核心结构多样性以靶向 von Hippel-Lindau E3 泛素连接酶:高效低氧诱导因子-1α稳定剂的研发。
J Med Chem. 2023 Sep 28;66(18):12776-12811. doi: 10.1021/acs.jmedchem.3c00434. Epub 2023 Sep 14.
2
Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction.利用小分子靶向 von Hippel-Lindau E3 泛素连接酶,破坏 VHL/HIF-1α 相互作用。
J Am Chem Soc. 2012 Mar 14;134(10):4465-8. doi: 10.1021/ja209924v. Epub 2012 Feb 27.
3
Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities.基于结构的小分子设计与优化,这些小分子靶向冯·希佩尔-林道(VHL)E3泛素连接酶与缺氧诱导因子(HIF)α亚基之间的蛋白质-蛋白质相互作用,具有体外纳摩尔亲和力。
J Med Chem. 2014 Oct 23;57(20):8657-63. doi: 10.1021/jm5011258. Epub 2014 Oct 6.
4
Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.小分子配体对 von Hippel-Lindau (VHL) E3 连接酶的发现及其作为抑制剂和 PROTAC 降解剂的应用。
Chem Soc Rev. 2022 Oct 3;51(19):8216-8257. doi: 10.1039/d2cs00387b.
5
Von Hippel-Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein.von Hippel-Lindau(VHL)小分子抑制剂结合增加了 VHL 蛋白的稳定性和细胞内水平。
J Biol Chem. 2021 Aug;297(2):100910. doi: 10.1016/j.jbc.2021.100910. Epub 2021 Jun 24.
6
Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene.缺氧诱导因子-1(HIF-1)和泛素在传统型肾细胞癌中的表达:与冯·希佩尔-林道肿瘤抑制基因突变的关系
Cancer Genet Cytogenet. 2003 Jun;143(2):145-53. doi: 10.1016/s0165-4608(02)00856-7.
7
Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298).基于群体的高效细胞激活的 von Hippel-Lindau(VHL)E3 泛素连接酶抑制剂的优化:结构-活性关系导致化学探针(2S,4R)-1-((S)-2-(1-氰基环丙甲酰胺基)-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺 (VH298)。
J Med Chem. 2018 Jan 25;61(2):599-618. doi: 10.1021/acs.jmedchem.7b00675. Epub 2017 Sep 18.
8
Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.在肾癌细胞中,因冯·希佩尔-林道肿瘤抑制基因功能缺失,缺氧诱导因子HIF-1α和HIF-2α在常氧条件下上调。
Oncogene. 2000 Nov 16;19(48):5435-43. doi: 10.1038/sj.onc.1203938.
9
Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.致癌突变导致VHL失活,这些突变破坏了pVHL.缺氧诱导转录因子-1α复合物的动态偶联。
J Biol Chem. 2005 Mar 4;280(9):7985-96. doi: 10.1074/jbc.M413160200. Epub 2004 Dec 20.
10
Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity.希佩尔-林道蛋白的C末端α-螺旋结构域在其E3泛素连接酶活性中的作用。
Oncogene. 2004 Mar 25;23(13):2315-23. doi: 10.1038/sj.onc.1207384.

引用本文的文献

1
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019-present).对招募冯·希佩尔-林道(VHL)的化学物质的专利综述:用于PROTACs的E3连接酶配体与靶向蛋白质降解(2019年至今)
Expert Opin Ther Pat. 2025 Feb 6;35(3):1-42. doi: 10.1080/13543776.2024.2446232.
2
Advancements in understanding the molecular mechanisms and clinical implications of Von Hippel-Lindau syndrome: A comprehensive review.冯·希佩尔-林道综合征分子机制及临床意义的研究进展:综述
Transl Oncol. 2025 Jan;51:102193. doi: 10.1016/j.tranon.2024.102193. Epub 2024 Nov 21.

本文引用的文献

1
Synthesis and Biological Activity of a VHL-Based PROTAC Specific for p38α.一种针对p38α的基于VHL的PROTAC的合成与生物活性
Cancers (Basel). 2023 Jan 18;15(3):611. doi: 10.3390/cancers15030611.
2
Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.VHL 配体的系统效力和性能评估及其对 PROTAC 设计的影响。
ChemMedChem. 2023 Apr 17;18(8):e202200615. doi: 10.1002/cmdc.202200615. Epub 2023 Feb 28.
3
Targeted Protein Degradation: Design Considerations for PROTAC Development.靶向蛋白降解:PROTAC 开发的设计考虑因素。
Curr Protoc. 2022 Dec;2(12):e611. doi: 10.1002/cpz1.611.
4
Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer.希佩尔-林道病:氧感应、蛋白降解和癌症的研究进展。
J Clin Invest. 2022 Sep 15;132(18):e162480. doi: 10.1172/JCI162480.
5
Development of the first non-hydroxamate selective HDAC6 degraders.开发首个非羟肟酸类选择性 HDAC6 降解剂。
Chem Commun (Camb). 2022 Oct 4;58(79):11087-11090. doi: 10.1039/d2cc03712b.
6
Targeting protein conformations with small molecules to control protein complexes.靶向小分子的蛋白质构象以控制蛋白质复合物。
Trends Biochem Sci. 2022 Dec;47(12):1023-1037. doi: 10.1016/j.tibs.2022.07.002. Epub 2022 Aug 16.
7
Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.小分子配体对 von Hippel-Lindau (VHL) E3 连接酶的发现及其作为抑制剂和 PROTAC 降解剂的应用。
Chem Soc Rev. 2022 Oct 3;51(19):8216-8257. doi: 10.1039/d2cs00387b.
8
Targeting the deubiquitinase USP7 for degradation with PROTACs.使用 PROTACs 靶向去泛素化酶 USP7 进行降解。
Chem Commun (Camb). 2022 Aug 4;58(63):8858-8861. doi: 10.1039/d2cc02094g.
9
E3 ligase ligand chemistries: from building blocks to protein degraders.E3 连接酶配体化学:从构建模块到蛋白质降解剂
Chem Soc Rev. 2022 May 10;51(9):3487-3534. doi: 10.1039/d2cs00148a.
10
E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points.成功的PROTACs中的E3连接酶配体:合成及连接点概述
Front Chem. 2021 Jul 5;9:707317. doi: 10.3389/fchem.2021.707317. eCollection 2021.